Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of recombinant Mycobacterium tuberculosis fusion protein (D-EC) skin test in adults
CTR20230091Phase 2Completed
- Sponsor
- Cansino Beijing
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel + epirubicin + cyclophosphamide in Tuberculosis (TB), pulmonary tuberculosis (TB), sponsored by Cansino Beijing. Started Jan 2023; status: completed.
02
Drugs
docetaxel + epirubicin + cyclophosphamide
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on CTR20230091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230091.